Lawless JW, Latham MC, Stephenson LS, Kinoti SN, Pertet AM, 1994. Iron supplementation improves appetite and growth in anaemic Kenyan primary school children. J Nutr 124 :645–654.
Carter JY, Lema OE, Mukunza HK, Varia HN, Munyere AS, Watkins WM, Watkins KM, 1999. Prevalence of anaemia in patients attending an outpatient clinic in western Rift Valley in Kenya during a low malaria season. East Afr Med J 76 :251–254.
Olsen A, Magnussen P, Ouma JH, Andreassen J, Friis H, 1998. The contribution of hookworm and other parasite infections to haemoglobin and iron status among children and adults in western Kenya. Trans R Soc Trop Med Hyg 92 :643–649.
Phillips RE, Looareesuwan S, Warell DA, Lee SH, Karbwang J, Warrell MJ, White NJ, Swasdichai C, Weatherall DJ, 1986. The importance of anaemia in cerebral and uncomplicated falciparum malaria: role of complications, dyserythropoiesis and iron sequestration. QJM 58 :305–323.
Weatherall DJ, Miller LH, Baruch DI, Marsh K, Doumbo OK, Casals-Pascual C, Roberts DJ, 2002. Malaria and the red cell. Hematology (Am Soc Hematol Educ Program) :35–57.
Masawe AEJ, Muindi JM, Swai GBR, 1974. Infections in iron deficiency and other types of anaemia in the tropics. Lancet ii :314–317.
Murray MJ, Murray AB, Murray MB, Murray CJ, 1978. The adverse effect of iron repletion on the course of certain infections. BMJ 2 :1113–1115.
Oppenheimer SJ, Gibson FD, Macfarlane SB, Moody JB, Harrison C, Spencer A, Bunari O, 1986. Iron supplementation increases prevalence and effects of malaria: report on clinical studies in Papua New Guinea. Trans R Soc Trop Med Hyg 80 :603–612.
Smith AW, Hendrickse RG, Harrison C, Hayes RJ, Greenwood BM, 1989. The effects on malaria of treatment of iron-deficiency anaemia with oral iron in Gambian children. Ann Trop Paediatr 9 :17–23.
Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, Acosta CJ, Schellenberg DM, Galindo CM, Kimario J, Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso PL, 1997. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350 :844–850.
Verhoef H, West CE, Nzyuko SM, de Vogel S, van der Valk R, Wanga MA, Kuijsten A, Veenemans J, Kok FJ, 2002. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. Lancet 360 :908–914.
Desai MR, Mei JV, Kariuki SK, Wannemuehler KA, Phillips-Howard PA, Nahlen BL, Kager PA, Vulule JM, ter Kuile FO, 2003. Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anaemia in western Kenya. J Infect Dis 187 :658–666.
Hutchings GH, Falco EA, Vanderwerff H, Russell PB, Elion GB, 1952. Antagonists of nucleic acid derivatives: 2,4-diaminopyrimidines. J Biol Chem 199 :43–56.
Waxman S, Herbert V, 1969. Mechanisms of pyrimethamine-induced megaloblastosis in human bone marrow. N Engl J Med 28 :1316–1319.
Matthews JI, Molitor JT, Hunt KK, 1973. Pyrimethamine induced leukopenia and thrombocytopenia in a patient with malaria and tropical sprue: case report. Mil Med 138 :280–283.
Strickland GT, Kostinas JE, 1970. Folic acid deficiency complicating malaria. Am J Trop Med Hyg 19 :910–915.
Fleming AF, 1989. Tropical obstetrics and gynaecology. 1. Anaemia in pregnancy in tropical Africa. Trans R Soc Trop Med Hyg 83 :441–448.
Boele van Hensbroek M, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, Greenwood BM, 1995. Iron, but not folic acid, combined with effective anti-malarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 89 :672–676.
Terlouw DJ, Courval JM, Kolczak MS, Rosenberg OS, Oloo AJ, Kager PA, Lal AA, Nahlen BL, ter Kuile FO, 2003. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in western Kenya. J Infect Dis 187 :467–476.
Topley E, 1998. Anaemia in Rural Africa: Community Support for Control Activities where Malaria is Common. Cambridge, United Kingdom: FSG MediMedia Ltd., 10–11.
White NJ, 2002. The assessment of antimalarial drug efficacy. Trends Parasitol 18 :458–464.
Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W, 2001. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358 :1218–1223.
Watkins WM, Brandling Bennet AD, Nevill CG, Carter JY, Boriga DA, Howells RE, Koech DK, 1988. Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans R Soc Trop Med Hyg 82 :398–403.
Pollitt E, 1993. Iron deficiency and cognitive function. Annu Rev Nutr 13 :521–537.
Pollitt E, Hathirat P, Kotchabhakdi NJ, Missell L, Valyasevi A, 1989. Iron deficiency and educational achievement in Thailand. Am J Clin Nutr 50 (Suppl 3):687–696.
Beasley NMR, Tomkins AM, Hall A, Lorri W, Kihamia CM, Bundy DAP, 2000. The impact of weekly iron supplementation on the iron status and growth of adolescent girls in Tanzania. Trop Med Int Health 5 :794–799.
Gera T, Sachdev HPS, 2002. Effect of iron supplementation on incidence of infectious illness in children: systematic review. BMJ 325 :1142–1144.
Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P, 2001. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357 :1471–1477.
Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW, 1998. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 59 :813–822.
Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL, 1998. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol 92 :141–150.
Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K, 1999. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 353 :632–636.
Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME, Marsh K, Taylor TE, Watkins WM, Winstanley PA, 2002. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 360 :1136–1143.
Sowunmi A, Fateye BA, 2003. Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. Trop Med Int Health 8 :783–792.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||375||221||3|
Malaria and anemia are common conditions in patients presenting to outpatient clinics in Kenya. Anemia is usually due to malaria infection with underlying micronutrient deficiency. Iron therapy has been shown to enhance recovery from anemia in children with malaria, without affecting malaria treatment. Iron and folic acid are often prescribed together for anemic individuals. Until recently in Kenya, the drug of first choice for non-severe malaria was sulfadoxine-pyrimethamine (SP), an antifolate antimalarial drug. In this study, 303 patients of all ages with anemia and uncomplicated Plasmodium falciparum malaria attending an outpatient clinic in an area of seasonal malaria were treated with SP and iron, and were randomized to receive folic acid. Parasite clearance rates were measured using a survival analysis plot for both parasitologic and clinical failure. There was a significant reduction in the efficacy of SP in patients taking standard therapeutic doses of folic acid using the survival curve for parasitologic failure (P < 0.0001), but no difference for clinical failure (P = 0.7008). Folic acid supplementation did not enhance recovery from anemia.